Comparing Aevi Genomic Medicine (GNMX) & Grifols (GRFS)
Aevi Genomic Medicine (NASDAQ: GNMX) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.
This table compares Aevi Genomic Medicine and Grifols’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aevi Genomic Medicine||N/A||-163.88%||-130.14%|
This table compares Aevi Genomic Medicine and Grifols’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Aevi Genomic Medicine||N/A||N/A||-$41.90 million||($0.96)||-1.28|
|Grifols||$4.48 billion||3.43||$603.60 million||$0.93||24.23|
Grifols has higher revenue and earnings than Aevi Genomic Medicine. Aevi Genomic Medicine is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of current ratings and target prices for Aevi Genomic Medicine and Grifols, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aevi Genomic Medicine||0||1||2||0||2.67|
Aevi Genomic Medicine currently has a consensus price target of $7.50, suggesting a potential upside of 509.76%. Given Aevi Genomic Medicine’s higher possible upside, equities analysts clearly believe Aevi Genomic Medicine is more favorable than Grifols.
Institutional and Insider Ownership
16.9% of Aevi Genomic Medicine shares are owned by institutional investors. Comparatively, 33.3% of Grifols shares are owned by institutional investors. 15.2% of Aevi Genomic Medicine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Risk and Volatility
Aevi Genomic Medicine has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Grifols has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.
Grifols pays an annual dividend of $0.28 per share and has a dividend yield of 1.2%. Aevi Genomic Medicine does not pay a dividend. Grifols pays out 30.1% of its earnings in the form of a dividend.
Grifols beats Aevi Genomic Medicine on 11 of the 14 factors compared between the two stocks.
About Aevi Genomic Medicine
Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohns disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.
Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics. It operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This segment offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. This segment serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment manufactures and installs products used by hospitals consisting of parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others segment sells intermediate biological products; and renders manufacturing services to third party companies. The company also offers engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.
Receive News & Stock Ratings for Aevi Genomic Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine Inc. and related stocks with our FREE daily email newsletter.